Pitavastatin sodium is a small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and is indicated in abnormal circulating lipid concentration and hyperlipidemia. It is grouped under the following drug class(es): Cholesterol-reducing agents, Lipid-lowering agents and Statins. Its therapeutic use is listed as cardiovascular. The directory classifies it as a discontinued API with a synthetic source/manufacturing origin. Other names for this substance include 6-Heptenoic acid, 7-(2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl)-3, 5-dihydroxy-, sodium salt (1:1), (3R, 5S, 6E)- and Livalo. Its PubChem CID is 23696934.
Pitavastatin sodium
| CAS No | 574705-92-3 |
|---|---|
| Molecular Formula | C25H23FNNaO4 |
| Molecular Weight | 443.4 g/mol |
| Synonyms | sodium;(E,3R,5S)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxyhept-6-enoate |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Pitavastatin sodium is a small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and is indicated in abnormal circulating lipid concentration and hyperlipidemia.
The listed CAS number is 574705-92-3.
The listed molecular formula is C25H23FNNaO4.
The listed molecular weight is 443.4 g/mol.
sodium;(E,3R,5S)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxyhept-6-enoate.
The source lists 6-Heptenoic acid, 7-(2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl)-3, 5-dihydroxy-, sodium salt (1:1), (3R, 5S, 6E)- and Livalo.